Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver’s strong clinical performance in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver cancer and the seventh most…
從這篇文章可以得到什麼：
- eTurboNews 文章僅供訂閱者使用。
- 訂閱是免費的。
- Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that Hepatology Communications published positive results from the ENCORE study validating HelioLiver’s strong clinical performance in detecting the presence of early hepatocellular carcinoma (HCC), the most common form of liver cancer and the seventh most….
